Sanofi (SNY) News Today $48.55 -0.06 (-0.12%) Closing price 07/14/2025 04:00 PM EasternExtended Trading$48.80 +0.25 (+0.52%) As of 07/14/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNY Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Sanofi’s Dupilumab Study: A Potential Game-Changer for Chronic Pruritus TreatmentJuly 14 at 12:59 PM | tipranks.comRegeneron and Sanofi’s Asthma Study: A Potential Game-Changer in TreatmentJuly 14 at 12:59 PM | tipranks.comBallentine Partners LLC Raises Stake in Sanofi (NASDAQ:SNY)July 13 at 5:31 AM | marketbeat.comSanofi (NASDAQ:SNY) Shares Purchased by Axxcess Wealth Management LLCJuly 13 at 4:22 AM | marketbeat.comFDA willing to trade faster drug reviews for lower prices, Bloomberg reportsJuly 12 at 12:20 PM | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNYJuly 12 at 10:00 AM | prnewswire.comU.S. Capital Wealth Advisors LLC Buys New Holdings in Sanofi (NASDAQ:SNY)July 12 at 4:29 AM | marketbeat.comSanofi’s Phase 2 Study on SAR444656: A Potential Game-Changer for Atopic DermatitisJuly 11, 2025 | tipranks.comSanofi’s Amlitelimab Study: A Long-Term Look at Atopic Dermatitis TreatmentJuly 11, 2025 | tipranks.comRegeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough for Lichen Simplex ChronicusJuly 11, 2025 | tipranks.comSanofi’s Promising Phase 2 Study on SAR447537 for AATD Emphysema: A Potential Game-ChangerJuly 11, 2025 | tipranks.comPfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert TestimonyJuly 11, 2025 | benzinga.comBrown Advisory Inc. Increases Holdings in Sanofi (NASDAQ:SNY)July 11, 2025 | marketbeat.comConcurrent Investment Advisors LLC Sells 28,246 Shares of Sanofi (NASDAQ:SNY)July 11, 2025 | marketbeat.comLeerink Partnrs Has Pessimistic View of Sanofi Q2 EarningsJuly 11, 2025 | americanbankingnews.comSanofi’s Chlamydia Vaccine Study: A Potential Game-Changer in PreventionJuly 10, 2025 | tipranks.comWhat is Zacks Research's Forecast for Sanofi Q1 Earnings?July 10, 2025 | marketbeat.comCode Waechter LLC Has $660,000 Stake in Sanofi (NASDAQ:SNY)July 10, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNYJuly 10, 2025 | gurufocus.comBank of New York Mellon Corp Sells 840,093 Shares of Sanofi (NASDAQ:SNY)July 10, 2025 | marketbeat.comLeerink Partnrs Has Strong Estimate for Sanofi Q3 EarningsJuly 10, 2025 | americanbankingnews.comSanofi’s Phase 2 Study on SAR444656: A Potential Breakthrough for Hidradenitis SuppurativaJuly 9, 2025 | tipranks.comSanofi’s Amlitelimab Study: Long-term Safety and Efficacy in Atopic DermatitisJuly 9, 2025 | tipranks.comSanofi’s Promising Phase 2 Study on Atopic Dermatitis Treatment: Key Insights for InvestorsJuly 9, 2025 | tipranks.comLeerink Partnrs Has Negative Forecast for Sanofi Q2 EarningsJuly 9, 2025 | marketbeat.comM&T Bank Corp Raises Stake in Sanofi (NASDAQ:SNY)July 9, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Shares Purchased by Envestnet Asset Management Inc.July 9, 2025 | marketbeat.comSanofi’s Promising Study on Amlitelimab for Celiac Disease: A Potential Game-ChangerJuly 8, 2025 | tipranks.comApogee Dives. But It Could Eventually Rival Sanofi's Biggest Moneymaker.July 8, 2025 | msn.comMay Hill Capital LLC Makes New Investment in Sanofi (NASDAQ:SNY)July 8, 2025 | marketbeat.comLeerink Partnrs Forecasts Sanofi's Q3 Earnings (NASDAQ:SNY)July 8, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNYJuly 7, 2025 | prnewswire.comApogee Reverses Lower Despite Promise For Twice-Yearly Eczema ShotJuly 7, 2025 | msn.comSanofi (NASDAQ:SNY) Shares Purchased by Raleigh Capital Management Inc.July 7, 2025 | marketbeat.comCallan Capital LLC Grows Position in Sanofi (NASDAQ:SNY)July 7, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Holdings Boosted by TD Private Client Wealth LLCJuly 7, 2025 | marketbeat.comWorld Investment Advisors Raises Stake in Sanofi (NASDAQ:SNY)July 7, 2025 | marketbeat.comSanofi (NASDAQ:SNY) Shares Purchased by Truist Financial CorpJuly 7, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Has $7.26 Million Position in Sanofi (NASDAQ:SNY)July 5, 2025 | marketbeat.comMirae Asset Global Investments Co. Ltd. Acquires 13,358 Shares of Sanofi (NASDAQ:SNY)July 5, 2025 | marketbeat.comSanofi’s Observational Study on Teplizumab: Implications for Type 1 Diabetes TreatmentJuly 4, 2025 | tipranks.comRegeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric AsthmaJuly 4, 2025 | tipranks.comSanofi’s Tolebrutinib Study: A Potential Game-Changer for Multiple Sclerosis TreatmentJuly 4, 2025 | tipranks.com10 Best Dip Stocks to Buy According to BillionairesJuly 4, 2025 | insidermonkey.comSanofi’s New Phase 2 Study: A Potential Game-Changer in Multiple Myeloma TreatmentJuly 3, 2025 | tipranks.comSanofi’s Phase 3 Study on Riliprubart: A Potential Game-Changer for CIDP Treatment?July 3, 2025 | tipranks.comUBS Sticks to Their Buy Rating for Sanofi (SNYNF)July 3, 2025 | theglobeandmail.comSanofi price target lowered to EUR 115 from EUR 125 at BarclaysJuly 2, 2025 | msn.comRegeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric AsthmaJuly 2, 2025 | tipranks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNYJuly 2, 2025 | prnewswire.com Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address SNY Media Mentions By Week SNY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNY News Sentiment▼0.810.99▲Average Medical News Sentiment SNY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNY Articles This Week▼4118▲SNY Articles Average Week Get Sanofi News Delivered to You Automatically Sign up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NVO News NVS News AZN News GSK News TAK News ARGX News BNTX News ONC News TEVA News INSM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNY) was last updated on 7/15/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sanofi Please log in to your account or sign up in order to add this asset to your watchlist. Share Sanofi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
